A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help with weight.
What this means for you
- Who can join
- Children and teens 12 to 17, have obesity.
- What you take
- orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 6.2 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity. Also studied in: Overweight.
Full scientific study title: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities.
Who can join
Children and teens 12 to 17, have obesity. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
- Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
- Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
- hypertension
- type 2 diabetes (T2D)
Key exclusion criteria
- Prepubertal (Tanner stage 1)
- Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening
- Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
- gastric bypass
- sleeve gastrectomy
Where this study is enrolling
This trial has 14 sites across 12 states. Contact a site coordinator directly to start screening.
California1 site
- Carey Chronis MD Pediatric, Infant and Adolescent MedicineVentura, California805-642-4704
Connecticut1 site
- Stamford Therapeutics ConsortiumStamford, Connecticut727-544-4842
Georgia1 site
- Children's Healthcare of Atlanta - Center for Advanced PediatricsAtlanta, Georgia404-712-4731
Illinois1 site
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois312-503-1499
Louisiana1 site
- Velocity Clinical ResearchLafayette, Louisiana337-519-4742
Mississippi1 site
- MedPharmics, LLCGulfport, Mississippi228-206-1283
Missouri1 site
- Sundance Clinical ResearchSt Louis, Missouri314-567-3377
North Carolina1 site
- Lucas Research, Inc.Morehead City, North Carolina252-222-5700
Pennsylvania1 site
- Childrens Hospital of PittsburghPittsburgh, Pennsylvania412-692-6935
Tennessee1 site
- Vanderbilt Health One Hundred OaksNashville, Tennessee615-322-6000
Texas3 sites
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchHouston, Texas
- La Providence Pediatrics Clinic - Chemidox Clinical TrialsHouston, Texas833-324-3643
- Martin Diagnostic ClinicTomball, Texas
Utah1 site
- Velocity Clinical Research, Salt Lake CitySouth Jordan, Utah
Timeline
Started enrolling: 2024-11-18. Expected completion: 2031-01. Last updated on ClinicalTrials.gov: 2026-05-27.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
